Bioxytran expands institutional investor base with $0.5M equity investment
- Bioxytran (OTCQB:BIXT) has entered into a common stock purchase agreement with TRITON FUNDS for $0.5M.
- The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing.
- The funding is sufficient to reach the next milestone of a submission of a Phase 3 regulatory trial in India for mild to moderate COVID-19.
- “Our investment not only serves to solidify our cost basis but, more importantly, empowers Bioxytran with the necessary capital infusion to propel them towards their impending milestone.” said Axel Olson, Equity Analyst and Entrepreneur in Residence at TRITON FUNDS.
- BIXT is -26.9% to $0.21.